GSK plc (NYSE:GSK) Shares Acquired by Beverly Hills Private Wealth LLC

Beverly Hills Private Wealth LLC increased its stake in GSK plc (NYSE:GSK - Free Report) by 94.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,397 shares of the pharmaceutical company's stock after acquiring an additional 14,288 shares during the period. Beverly Hills Private Wealth LLC's holdings in GSK were worth $994,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in GSK. Dodge & Cox boosted its stake in GSK by 0.5% in the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock worth $2,314,672,000 after purchasing an additional 353,749 shares in the last quarter. FMR LLC grew its position in shares of GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after acquiring an additional 23,814,104 shares during the period. Primecap Management Co. CA raised its stake in shares of GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after buying an additional 10,407,905 shares during the period. Fisher Asset Management LLC lifted its holdings in GSK by 1.4% during the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock valued at $637,061,000 after purchasing an additional 259,867 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in GSK by 0.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock valued at $255,914,000 after acquiring an additional 35,134 shares during the period. Institutional investors own 15.74% of the company's stock.

GSK Stock Performance

Shares of GSK stock traded down $0.39 on Wednesday, hitting $37.11. The company had a trading volume of 5,029,444 shares, compared to its average volume of 4,772,848. The firm has a market cap of $76.57 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The company has a 50-day moving average price of $37.71 and a 200-day moving average price of $36.02. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same period in the previous year, the company posted $0.43 earnings per share. The business's revenue was up 2.1% on a year-over-year basis. As a group, equities research analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.54%. GSK's dividend payout ratio (DPR) is currently 86.60%.

Analyst Ratings Changes

GSK has been the topic of a number of research analyst reports. Hsbc Global Res upgraded GSK to a "strong sell" rating in a research report on Monday, April 28th. StockNews.com raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 24th. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.